ArticleInfectious diseases and therapy2024

Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.

Myron J Levin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.